NT-proBNP can be determined in a biological sample using at least one antibody which recognizes an epitope of NT-proBNP in both a glycosylated and non-glycosylated form of NT-proBNP. Said antibody is preferably an isolated polyclonal antibody or a mixture of monoclonal antibodies coated onto a particle, preferably coated onto said particle in a coating ratio of 6-60%, forming a layer or multiple layers of antibodies on said particle. The assay, realized in the form of a nephelometric or turbidimetric assay, can be applied to a wide range of automated clinical analyzers.

NT-proBNP can be determined in a biological sample using at least one antibody which recognizes an epitope of NT-proBNP in both a glycosylated and non-glycosylated form of NT-proBNP. Said antibody is preferably an isolated polyclonal antibody or a mixture of monoclonal antibodies coated onto a particle, preferably coated onto said particle in a coating ratio of 6-60%, forming a layer or multiple layers of antibodies on said particle. The assay, realized in the form of a nephelometric or turbidimetric assay, can be applied to a wide range of automated clinical analyzers.

A method for pre-analytical treatment of a serum or plasma sample from a patient suspected of suffering from oxidative stress, which includes contacting the sample with one or more microcapsules having a gelled alginate core and a semipermeable coating, where the alginate core includes dispersed receptors against an oxidised human parathyroid hormone (PTH) peptide. The semipermeable membrane can be obtained by layer-by-layer deposition of polycationic and polyanionic macromolecules onto the gelled core, following by hardening, crosslinking and co-acervation of the macroionic phases.

Antibodies that modulate insulin receptor signaling are provided.

Antibodies that modulate insulin receptor signaling are provided.

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy or to prevention of symptoms of illness and/or for use in therapy or prevention of diseases characterized by said symptoms. The symptoms of illness may be selected from the group of nausea, headache, muscle aches, back pain, shivering, vomiting in a subject wherein said antibody or fragment or scaffold may bind to ADM of amino acids 1 to 52 (SEQ ID NO: 1), or to fragments thereof.

The present invention relates to specific antibodies and use thereof, such as for identifying and/or quantifying liraglutide fibrils and/or semaglutide fibrils.

The present invention relates to specific antibodies and use thereof, such as for identifying and/or quantifying liraglutide fibrils and/or semaglutide fibrils.

Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.